mRNA Cap Analog Synthesis Without Ion-Exchange Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high cost and lengthy production process of trinucleotide cap analogs used in mRNA vaccines, particularly due to extensive purification steps and ion-exchange chromatography, hinder rapid and economical production of mRNA for infectious disease vaccines.
Innovation Solution
A cap analog compound (Chemical Formula 1) is synthesized in fewer steps with reduced purifications, enhancing in vitro transcription efficiency and protein expression by integrating it during mRNA synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If trinucleotide cap analogs are used in mRNA vaccine production, then mRNA transcription efficiency and protein expression are improved, but production cost increases and production time lengthens due to extensive purification steps
Solution Approach 1:
The patent extracts and eliminates the extensive purification steps (ion-exchange chromatography) from the cap analog production process while maintaining the essential capping function. The simplified synthesis method removes unnecessary purification operations that consumed time and resources, keeping only the critical steps needed to produce functional cap analogs for mRNA vaccination.
Solution Approach 2:
The patent skips the lengthy ion-exchange chromatography purification steps that traditionally followed cap analog synthesis. By using alternative purification methods or eliminating these steps entirely, the process rushes through to completion much faster, reducing production time from what would normally be extended periods to significantly shorter durations while still producing effective cap analogs.
2Productivity
If trinucleotide cap analogs are used in mRNA vaccine production, then mRNA transcription efficiency and protein expression are improved, but production cost increases
Solution Approach 1:
The patent extracts and removes the costly ion-exchange chromatography purification steps from the manufacturing process. By eliminating these expensive operational steps while maintaining cap analog effectiveness, the overall production cost is significantly reduced without sacrificing the ability to produce functional mRNA vaccines.
Solution Approach 2:
The patent employs a simplified, more cost-effective synthesis approach that uses cheaper reagents and procedures compared to the traditional trinucleotide cap analog methods. This disposable-like simplified process prioritizes cost-efficiency and ease of manufacture over the more expensive, complex traditional methodology.
3Manufacturing precision
If extensive purification steps including ion-exchange chromatography are used, then cap analog purity is improved, but production time and cost increase
Solution Approach 1:
The patent extracts and eliminates the time-consuming ion-exchange chromatography steps from the purification sequence. By removing these extensive purification operations while implementing alternative, faster purification methods, the process achieves sufficient cap analog purity without the time penalty of traditional approaches.
Solution Approach 2:
The patent skips the lengthy ion-exchange chromatography purification steps and rushes through to completion using alternative methods. This allows the process to achieve adequate purity levels much faster, sacrificing some of the ultra-high purity benefits of extensive chromatography in favor of dramatically reduced production time.
4Manufacturing precision
If extensive purification steps including ion-exchange chromatography are used, then cap analog purity is improved, but production cost increases
Solution Approach 1:
The patent extracts and removes the expensive ion-exchange chromatography purification steps from the manufacturing process. By eliminating these costly operations while maintaining adequate cap analog purity through alternative methods, the overall production cost is significantly reduced without completely sacrificing product quality.
Solution Approach 2:
The patent employs cheaper purification and synthesis methods that replace the expensive traditional ion-exchange chromatography approach. This disposable-like simplified methodology prioritizes cost-effectiveness over the ultra-high purity and precision of traditional methods, making mRNA vaccine production more economically viable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cap analog significantly increases mRNA transcription and protein expression efficiency while reducing production time and costs, making it suitable for rapid production of mRNA vaccines.
Implementation Method 1
For in vitro transcription of mRNA molecules, the following components are required: a linearized DNA template, an RNA polymerase (mainly T7 RNA polymerase), four ribonucleoside triphosphates (NTPs) A, G, C, and U (or 1-Methylpseudouridine (m1Ψ)), and a cap analog.
Implementation Method 2
The 5′ cap structure may protect the 5′ end of mRNA from biodegradation by 5′ exonuclease
Implementation Method 3
Particularly, the 5′ cap structure is recognized by a eukaryotic translation initiation factor 4E (eIF4E) to form a translation initiation complex, playing an important in protein expression.
Implementation Method 4
The high cost and lengthy production process of trinucleotide cap analogs used in mRNA vaccines, particularly due to extensive purification steps and ion-exchange chromatography
Data Source
AI summary
Provided are a compound of chemical formula 1, a cap analog comprising same, mRNA capped with the cap analog, a method for preparing mRNA by using the cap analog, a use of using the cap analog for preparing mRNA, and a pharmaceutical composition for expressing a target peptide or protein, comprising mRNA 5′-capped with the cap analog.